The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro

@article{Caly2020TheFD,
  title={The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro},
  author={L. Caly and J. Druce and M. Catton and D. Jans and K. Wagstaff},
  journal={Antiviral Research},
  year={2020},
  volume={178},
  pages={104787 - 104787}
}
Abstract Although several clinical trials are now underway to test possible therapies, the worldwide response to the COVID-19 outbreak has been largely limited to monitoring/containment. We report here that Ivermectin, an FDA-approved anti-parasitic previously shown to have broad-spectrum anti-viral activity in vitro, is an inhibitor of the causative virus (SARS-CoV-2), with a single addition to Vero-hSLAM cells 2 h post infection with SARS-CoV-2 able to effect ~5000-fold reduction in… Expand

Paper Mentions

Interventional Clinical Trial
The study aims to test whether Ivermectin would decrease mortality and reduces chances of getting infected with corona virus, improve management of clinical symptoms and reduce length… Expand
ConditionsIvermectin, SARS-CoV-2
InterventionDrug, Other
Interventional Clinical Trial
Treatment of mild COVID-19 is basically performed at an outpatient clinic, then when the symptom and clinical findings exacerbate to a moderate level, patients are admitted. There is… Expand
ConditionsCovid19
InterventionDrug
Interventional Clinical Trial
Recent study reported in vitro synergistic interaction between two FDA approved drugs, remdesivir (RDV) and ivermectin (IVM) resulting in enhanced antiviral activity against SARS… Expand
ConditionsCovid19
InterventionDrug
Interventional Clinical Trial
It is a single-center, prospective, randomized, double-blind, placebo-controlled study carried out by the Ministry of Public Health of the Province of Corrientes, Argentina, in… Expand
ConditionsCovid19
InterventionDrug
Search for SARS-CoV-2 inhibitors in currently approved drugs to tackle COVID-19 pandemia
ABSTRACT Different treatments are currently used for clinical management of SARS-CoV-2 infection, but little is known about their efficacy yet. Here we present ongoing results to compare currentlyExpand
Ivermectin: an award-winning drug with expected antiviral activity against COVID-19
TLDR
Challenges surrounding the use of ivermectin in the context of coronavirus disease-19 (COVID-19) and how novel formulations employing micro- and nanotechnologies may address these concerns are discussed. Expand
Antiviral Activity of Ivermectin Against SARS-CoV-2: An Old-Fashioned Dog with a New Trick—A Literature Review
TLDR
The evidence derived from docking and modeling analysis, in vitro and in vivo studies, and results from new investigational drug protocols, as well as clinical trials, if available, which will be effective in supporting the prospective use of ivermectin as an alternative treatment for COVID-19 are summarized. Expand
Ivermectin as a potential COVID-19 treatment from the pharmacokinetic point of view
TLDR
The available pharmacokinetic data from clinically relevant and excessive dosing studies indicate that the SARS-CoV-2 inhibitory concentrations are not likely to be attainable in humans. Expand
Ivermectin as a potential COVID-19 treatment from the pharmacokinetic point of view: antiviral levels are not likely attainable with known dosing regimens
TLDR
The available pharmacokinetic data from clinically relevant and excessive dosing studies indicate that the SARS-CoV-2 inhibitory concentrations are not likely to be attainable in humans. Expand
The mechanisms of action of Ivermectin against SARS-CoV-2: An evidence-based clinical review article
Considering the urgency of the ongoing COVID-19 pandemic, detection of various new mutant strains and future potential re-emergence of novel coronaviruses, repurposing of approved drugs such asExpand
Recent advances in developing small-molecule inhibitors against SARS-CoV-2
TLDR
The potential therapeutic targets involved in the life cycle of the virus are summarized and small-molecule prophylactic and therapeutic agents have been or are being developed for prevention and treatment of SARS-CoV-2 infection. Expand
Pre-clinical search of SARS-CoV-2 inhibitors and their combinations in approved drugs to tackle COVID-19 pandemic
TLDR
Existing drugs approved for human use in a variety of diseases are screened to compare how they counteract SARS-CoV-2-induced cytopathic effect and viral replication in vitro, and several drug combinations are assessed to decrease the potential emergence of resistant viruses. Expand
A Wonder Drug in the Arsenal against COVID - 19: Medication Evidence from Ivermectin
TLDR
These documentations serve as a ray of hope for considering ivermectin in treating CO VID-19 due to its suggested nuclear transport inhibitory mechanism and warrant detailed investigations for understanding its benefit in terms of efficacy and safety in COVID-19 patients. Expand
Moxidectin and ivermectin inhibit SARS-CoV-2 replication in Vero E6 cells but not in human primary airway epithelium cells
TLDR
Findings suggest that, even by using a high-dose regimen of ivermectin or switching to another drug in the same class are unlikely to be useful for treatment against SARS-CoV-2 in humans. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 44 REFERENCES
Discovering drugs to treat coronavirus disease 2019 (COVID-19).
TLDR
This article summarizes agents with potential efficacy against SARS-CoV-2 and indicates some promising results have been achieved thus far. Expand
The Pharmacokinetics and Interactions of Ivermectin in Humans—A Mini-review
TLDR
A brief review of the information availabile regarding the pharmacokinetics and interactions of ivermectin in humans suggests awareness of these characteristics could improve the clinical efficacy of IvermECTin. Expand
Lack of efficacy of ivermectin for prevention of a lethal Zika virus infection in a murine system.
TLDR
ivermectin was found to be ineffective for prevention of a lethal infection with the Senegal strain of Zika virus in Ifnar1 knockout mice. Expand
Therapeutic options for the 2019 novel coronavirus (2019-nCoV)
TLDR
The potential for repurposing existing antiviral agents to treat 2019-nCoV infection (now known as COVID-19) is discussed, some of which are already moving into clinical trials. Expand
Anti-HCV, nucleotide inhibitors, repurposing against COVID-19
TLDR
The results suggest the effectiveness of Sofosbuvir, IDX-184, Ribavirin, and Remidisvir as potent drugs against the newly emerged HCoV disease. Expand
Ivermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity: new prospects for an old drug.
TLDR
Ivermectin, a broadly used anti-helminthic drug, proved to be a highly potent inhibitor of YFV replication and inhibited, although less efficiently, the replication of several other flaviviruses, i.e. dengue fever, Japanese encephalitis and tick-borne encephalopathy viruses. Expand
The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus
TLDR
The selectivity value for RDV-TP obtained here with a steady-state approach suggests that it is more efficiently incorporated than ATP and two other nucleotide analogs, which may explain the high potency of RDV against RNA viruses in cell-based assays. Expand
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro
TLDR
This study evaluated the antiviral efficiency of five FAD-approved drugs including ribavirin, penciclovir, nitazoxanide, nafamostat, chloroquine and two well-known broad-spectrum antiviral drugs remdesivir and favipiravir against a clinical isolate of 2019-nCoV in vitro. Expand
The broad spectrum antiviral ivermectin targets the host nuclear transport importin α/β1 heterodimer.
TLDR
It is shown here that ivermectin's broad spectrum antiviral activity relates to its ability to target the host importin (IMP) α/β1 nuclear transport proteins responsible for nuclear entry of cargoes such as integrase and NS5. Expand
Nuclear localization of dengue virus (DENV) 1-4 non-structural protein 5; protection against all 4 DENV serotypes by the inhibitor Ivermectin.
TLDR
The small-molecule inhibitor Ivermectin was inhibitory towards both DENV 1 and 2 NS5 interaction with its nuclear transporter importin α/β in vitro, and protected against infection from DENV1-4, and has potential in the clinical setting as a dengue antiviral. Expand
...
1
2
3
4
5
...